Meme Kanserinde Lokal Tedaviler

Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer. 2018;96:17.

Dawood S, Haaland B, Albaracin C, Gupta S, Cortes J, Sim YY, et al. Is the proportion of patients diagnosed with synchronous Stage IV breast cancer who survive more than two years increasing over time? Oncology. 2015;89(2):79–85.

Chia SK, Speers CH, D’yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110(5):973–979.

Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E, et al. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 2017;55:16–23.

Merloni F, Palleschi M, Gianni C, Sirico M, Serra R, Casadei C, et al. Local treatment for oligoprogressive metastatic sites of breast cancer: Efficacy, toxicities and future perspectives. Clinical & Experimental Metastasis. 2024;41(6):863–875.

Kinoshita T, Iwamoto E, Tsuda H, et al. Radiofrequency ablation as local therapy for early breast carcinomas. Breast Cancer. 2011;18(1):10–17..

Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery. 2002;132(4):605–611.

Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, et al. Radiofrequency ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Archives of Surgery. 2006;391(2):118–123.

Sieghart W, Hucke F, Peck-Radosavljevic M. Transarteriyel kemoembolizasyon: Modaliteler, endikasyon ve hasta seçimi. Journal of Hepatology. 2015;62:1187–1195.

Lencioni R, Petruzzi P, Crocetti L. Hepatosellüler karsinomun kemoembolizasyonu. Seminars in Interventional Radiology. 2013;30(1):3–11.

Qiu B, Aili A, Xue L, Jiang P, Wang J. Advances in radiobiology of stereotactic ablative radiotherapy. Frontiers in Oncology. 2020;10:1165.

Fietz T, Tesch H, Rauh J, et al. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study. Breast. 2017;34:122–130.

Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? Journal of the National Cancer Institute. 2010;102(7):456–463.

Guarneri V, Conte P. Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. The Oncologist. 2009;14(7):645–656.

Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Annals of Oncology. 2017;28(1):16–33.

Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology. 2020;148:157–166.

Rivera K, Rohan D, Washington K. Hepatectomy, RFA, and other liver directed therapies for treatment of breast cancer liver metastasis: A systematic review. Frontiers in Oncology. 2021;11:1–11.

Merloni F, Palleschi M, Gianni C, Sirico M, Serra R, Casadei C, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (CURB): An open-label, randomised, controlled, phase 2 study. The Lancet Oncology. 2024;25(6):1–11.

Alomran R, Beyaz M, Bruce M, Bressel M, Hamamcıoğlu S, Karroum L, Hanna GG, Siva S, Goel S, David S. Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR study). J Clin Oncol. 2024;42(16_suppl):1087. https://doi.org/10.1200/JCO.2024.42.16_suppl.1087

Chow R, Hoskin P, Schild SE, Raman S, Im J, Zhang D, Chan S, Chiu N, Chiu L, Lam H, Chow E, Lock M. Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiother Oncol. 2019;141:56. https://doi.org/10.1016/j.radonc.2019.08.023

Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4–12. https://doi.org/10.1016/j.prro.2016.08.001

Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998;77(2):336. https://doi.org/10.1038/bjc.1998.51

Noble J, Sirohi B, Ashley S, Ladas G, Smith I. Sternal/para-sternal resection for parasternal local recurrence in breast cancer. Breast. 2010;19(5):350. https://doi.org/10.1016/j.breast.2010.03.016

Yoshimoto M, Tada K, Nishimura S, Makita M, Iwase T, Kasumi F, Okumura S, Sato Y, Nakagawa K. Favourable long-term results after surgical removal of lung metastases of breast cancer. Breast Cancer Res Treat. 2008;110(3):485–490. https://doi.org/10.1007/s10549-007-9735-7 25. Meimarakis G, Rüttinger D, Stemmler J, Crispin A, Weidenhagen R, Angele M, Fertmann J, Hatz RA, Winter H. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg. 2013;95(4):1170–1180. https://doi.org/10.1016/j.athoracsur.2012.12.007

Milano MT, Katz AW, Schell MC, Philip A, Okunieff P. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(5):1516-1522. doi:10.1016/j.ijrobp.2008.06.1935

Uptodate the role of local therapies in metastatic breast cancer (07.05.2025 tarihinde http://www.uptodate.com/contents/the-role-of-local-therapies-in-metastatic-breast-cancer bu siteden bilgi alınmıştır)

Takayama S, Kinoshita T, Shiino S, Jimbo K, Watanabe K, Fujisawa T, Yamamoto N, Onishi T, Shien T, Ito M, Takahashi M, Futamura M, Aruga T, Kaneko K, Suto A. Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) Study under the Patient-proposed Health Services. JMA J. 2023;6(4):505-512. doi:10.31662/jmaj.2023-0047

Xia L-Y, Hu Q-L, Xu W-Y. Efficacy and Safety of Radiofrequency Ablation for Breast Cancer Smaller Than 2 cm: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:651646. doi:10.3389/fonc.2021.65164